Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539 https://t.co/mb3Eof2Uiv https://t.co/3i3ZTY25ru

• Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Pat…

Ab0676 #ACR22 Adrenal hemorrhage in APLS 59 pts from SLE cohort + 181 from lit review 65% prior VTE, 12% CVA, 24% OB morbidity 46% thrombocyt, 21% had SLE 58% on a/c 69% b/l hemorrhage 63% adrenal insuff Radiol remission: 6% at 1 yr, 41% at 5yr Death 2% 1 yr, 11% at 5 @RheumNow https://t.co/EacifcN7Sd

Ab0683 #ACR22 aPL Pts ANA pos vs neg: 521 pts with +aPL Ab WO other autoimmune disease 224 +ANA, 297 -ANA ANA+ ass w/ hemolytic anemia, thrombocyt, leukopenia, livedo, unexplained fetal death Trend for arthritis, aPL nephropathy @RheumNow https://t.co/3NHGymyL1C

Ab0674 #ACR22 HIT AND APLS?? Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE with aPL Ab: Not one ultimately met clinical criteria for HIT 1 pt had PF4 antibodies, SRA testing negative in ALL cases Thrombocytopenia w/ aPL Abs? Think APS 1st! @Rheumnow https://t.co/ZYZP5VZF0R

Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment response in SLE nephritis . CD163 AUC 0.83 vs 0.75 for UPCR @THKC1 @RheumNow #ACR22 Abstr#0536 https://t.co/YI3JC2uKcv https://t.co/jnkfbI0Z1M

• Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response…

Here is a quick recap on #ACR22 Abstr#0355 Effect of voclosporin in class V lupus nephritis #lupus https://t.co/0cR8On5UWN via @YouTube @RheumNow https://t.co/E25so6X2fj

• Effect of voclosporin in class V lupus nephritis - YouTube

Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow https://t.co/FeYrdlwQsA

• Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneou…

Gomez et al. Predictors renal flare in SLE. Adjusted models - low C3, low albumin, proteinuria. @RheumNow #ACR22 Abstr#0540 https://t.co/POfeAa9Ao9 https://t.co/a3JkSP1MkX

• Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A P…

Jorge et al. @AprilJorgeMD Incidence SLE nephritis - 16% onset, 35% 15 years. 44.7% men vs 28.6% women at 10 years. 40% Black, 38% Hispanic, 40% Asian, 23% White. @RheumNow #ACR22 Abstr#0538 https://t.co/Nbx16jZAN7 https://t.co/BEnAtbcIHt

• Contemporary Incidence of Lupus Nephritis Among Patients with Systemic Lupus Er…

Tofighi et al. VTE in SLE nephritis. 10% VTE, 5.2% VTE after SLE nephritis diagnosis. Risks - Black patients, ds-DNA+, SDI, aPL+, SLEDAI. @RheumNow #ACR22 Abstr#0541 https://t.co/G6q0qvirf7 https://t.co/B8STBTMy14

• Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Fa…

Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction: 🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts. #ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A

Abst0338 #ACR22 Transition from CLE to SLE 324 cases of incident cutaneous lupus, mean f/u 8 years 26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years Risk factors: SCLE, younger age, recent diagnosis @RheumNow #ACRBest https://t.co/JFcUIkfA9n